VEGFR-2

Isoforms Recommended:	VEGFR2/KDR/Flk-1

By Targets:	VEGFR (218) Akt (2) Antibiotic (1) Apoptosis (53) Aurora Kinase (6) Autophagy (23) Bacterial (2) Bcl-2 Family (2) Bcr-Abl (2) c-Fms (7) c-Kit (25) c-Met/HGFR (17) Carbonic Anhydrase (4) Casein Kinase (2) Caspase (1) CDK (4) Checkpoint Kinase (Chk) (1) Complement System (2) Dihydrofolate reductase (DHFR) (2) Discoidin Domain Receptor (2) Drug Metabolite (3) EGFR (11) Endogenous Metabolite (1) Ephrin Receptor (3) ERK (2) FAK (2) Ferroptosis (3) FGFR (28) FLT3 (21) Fungal (2) GSK-3 (2) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) HSP (2) HSV (1) IAP (1) IKK (1) Integrin (2) Interleukin Related (1) IRE1 (3) Isotope-Labeled Compounds (6) JAK (2) LRRK2 (1) MAP3K (1) MDM-2/p53 (3) MEK (1) Microtubule/Tubulin (2) Mitophagy (3) Mixed Lineage Kinase (2) mTOR (1) Necroptosis (1) NF-κB (1) PDGFR (46) PERK (1) PI3K (3) PROTACs (5) Raf (9) Reactive Oxygen Species (2) RET (10) Src (12) Survivin (1) Syk (1) TAM Receptor (8) Tie (7) Topoisomerase (2) Trk Receptor (4)
By Research Areas:	Cancer (213) Cardiovascular Disease (18) Endocrinology (1) Infection (6) Inflammation/Immunology (19) Metabolic Disease (3) Neurological Disease (1)

Targets Recommended: VEGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103002

SU5408 3 Publications Verification VEGFR2 Kinase Inhibitor I	VEGFR	Cardiovascular Disease
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of *VEGFR2* kinase with an IC₅₀ of 70 nM.

HY-160259

VEGFR-2-IN-39	PROTACs VEGFR	Cardiovascular Disease
VEGFR-2-IN-39, a PROTAC, displays potent inhibitory activity against *VEGFR-2. VEGFR-2-IN-39 concentration-dependently inhibited proliferation of HUVECs (EA.hy926 bearing VEGFR-2*) with IC₅₀ of 32.793 µM .

HY-147926

VEGFR-2-IN-28	VEGFR Apoptosis	Cancer
VEGFR-2-IN-28 (compound 12c) is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.83 µM. VEGFR-2-IN-28 induces apoptosis and has anticancer activity .

HY-147902

VEGFR-2-IN-24

VEGFR Cancer

VEGFR-2-IN-24 is a potent VEGFR-2 inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research .

VEGFR-2-IN-24	VEGFR	Cancer
VEGFR-2-IN-24 is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research .

HY-155610

VEGFR-2-IN-32	VEGFR	Cancer
VEGFR-2-IN-32 (Comp 3a) is an inhibitor of *VEGFR-2* with an IC₅₀ of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC₅₀ of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research .

HY-155464

VEGFR-2/AURKA-IN-1	VEGFR Aurora Kinase	Cancer
VEGFR-2/AURKA-IN-1 (compound 5e) is a thiazolidin-4-one derivative with antiglioma activity (IC₅₀: 6.43 μM, LN229). VEGFR-2/AURKA-IN-1 has affinity for AURKA and VEGFR-2 and is a potential ligand. VEGFR-2/AURKA-IN-1 causes DNA strand breaks and exhibits cytotoxic and anticancer potential .

HY-145864

VEGFR-2-IN-12	VEGFR	Cancer
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.037 µM. VEGFR-2-IN-12 shows high growth inhibition against MCF-7 cells (GI₅₀=1.6 µM). VEGFR-2-IN-12 has antitumor activity .

HY-155242

VEGFR-2-IN-36	VEGFR Bcl-2 Family Apoptosis	Cancer
VEGFR-2-IN-36 (compound 15) is a VEGFR-2 inhibitor (IC₅₀: 0.067 μM) and inducer of apoptosis with anticancer activity. VEGFR-2-IN-36 upregulates BAX levels and downregulates Bcl-2 levels. VEGFR-2-IN-36 is toxic to cancer cells, MCF-7 (IC₅₀=0.42 μM) and HepG2 (IC₅₀=0.22 μM) .

HY-155239

VEGFR-2-IN-35	VEGFR	Cancer
VEGFR-2-IN-35 (compound 7) is a potent VEGFR-2 inhibitor with IC₅₀=37 nM. VEGFR-2-IN-35 inhibits MCF-7 and HCT 116 cancer cells with IC₅₀ values of 10.56 and 7.07 μM, respectively .

HY-18926

VEGFR2-IN-7

VEGFR2-IN-7 (compound E) is an inhibitor of VEGFR2. VEGFR2-IN-7 can used in study cancers .

VEGFR2-IN-7
VEGFR2-IN-7 (compound E) is an inhibitor of *VEGFR2. VEGFR2*-IN-7 can used in study cancers .

HY-145849

VEGFR2-IN-1	VEGFR	Cancer
VEGFR2-IN-1 is a potent and selective *VEGFR2* inhibitor (IC₅₀=19.8 nM). VEGFR2-IN-1 inhibits cell proliferation and migration through apoptosis activation and *VEGFR2* inhibition .

HY-149361

VEGFR2-IN-4	VEGFR	Inflammation/Immunology
VEGFR2-IN-4 (compound 25) is a potent and selective VEGFR2 kinase inhibitor, with a GI₅₀ of 0.7 nM. VEGFR2-IN-4 shows anti-angiogenic effect. VEGFR2-IN-4 can be used for the research of rheumatoid arthritis .

HY-162326

VEGFR-2-IN-41	VEGFR Apoptosis	Cancer
VEGFR-2 IN-41 (Compound 8) is a *VEGFR-2* inhibitor with IC₅₀ 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity .

HY-147133

VEGFR2-IN-2

VEGFR Cancer

VEGFR2-IN-2 (compound 6e) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

VEGFR2-IN-2	VEGFR	Cancer
VEGFR2-IN-2 (compound 6e) is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

HY-W800162

VEGFR-2-IN-37	VEGFR	Cancer
VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .

HY-153158

VEGFR2-IN-3

VEGFR Cancer

VEGFR2-IN-3 (compound 385) is a potent VEGFR2 inhibitor .

VEGFR2-IN-3	VEGFR	Cancer
VEGFR2-IN-3 (compound 385) is a potent *VEGFR2* inhibitor .

HY-147872

VEGFR-2-IN-22	VEGFR Microtubule/Tubulin Apoptosis	Cancer
VEGFR-2-IN-22 (Compound 25) is a dual *VEGFR-2* and β-tubulin polymerization inhibitor with an IC₅₀ of 19.82 nM against VEGFR-2. VEGFR-2-IN-22 induces apoptosis .

HY-148040

VEGFR-2-IN-29

VEGFR Cancer

VEGFR-2-IN-29 (Compound 5) is a VEGFR-2 inhibitor with an IC₅₀ of 16.5 nM .
HY-144804

VEGFR-2-IN-17

VEGFR Cancer

VEGFR-2-IN-17 (Compound 15a) is a potent VEGFR-2 inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .
HY-144803

VEGFR-2-IN-16

VEGFR Cancer

VEGFR-2-IN-16 (Compound 15b) is a potent VEGFR-2 inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .
HY-147800

VEGFR-2-IN-21

VEGFR Cancer

VEGFR-2-IN-21 (Compound 5d) is a potent VEGFR-2 inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity .
HY-146236

VEGFR-2-IN-27

VEGFR Cancer

VEGFR-2-IN-27 (compound 7a) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer .
HY-18625

VEGFR-2-IN-5

VEGFR Cancer

VEGFR-2-IN-5 is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .
HY-18625A

VEGFR-2-IN-5 hydrochloride

VEGFR Cancer

VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .

VEGFR-2-IN-29	VEGFR	Cancer
VEGFR-2-IN-29 (Compound 5) is a *VEGFR-2* inhibitor with an IC₅₀ of 16.5 nM .

VEGFR-2-IN-17	VEGFR	Cancer
VEGFR-2-IN-17 (Compound 15a) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .

VEGFR-2-IN-16	VEGFR	Cancer
VEGFR-2-IN-16 (Compound 15b) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .

VEGFR-2-IN-21	VEGFR	Cancer
VEGFR-2-IN-21 (Compound 5d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity .

VEGFR-2-IN-27	VEGFR	Cancer
VEGFR-2-IN-27 (compound 7a) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer .

VEGFR-2-IN-5	VEGFR	Cancer
VEGFR-2-IN-5 is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

VEGFR-2-IN-5 hydrochloride	VEGFR	Cancer
VEGFR-2-IN-5 hydrochloride is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

HY-144805

VEGFR-2-IN-18	VEGFR Apoptosis	Cancer
VEGFR-2-IN-18 (Compound 15d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60 nM. VEGFR-2-IN-18 induces cell apoptosis. VEGFR-2-IN-18 shows antitumor activities .

HY-145856

VEGFR-2-IN-11	VEGFR Apoptosis	Cancer
VEGFR-2-IN-11 (Compound 8h) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis .

HY-146229

VEGFR-2-IN-25

VEGFR Cancer

VEGFR-2-IN-25 (compound 5d) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer .

VEGFR-2-IN-25	VEGFR	Cancer
VEGFR-2-IN-25 (compound 5d) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer .

HY-146492

VEGFR-2/BRAF-IN-2	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .

HY-144795

VEGFR-2-IN-14	VEGFR Apoptosis	Cancer
VEGFR-2-IN-14 (Compound 5) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-14 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis .

HY-157960

VEGFR-2-IN-42

VEGFR Cancer

VEGFR-2-IN-42 (compound 8c) is a potent VEGFR-2 inhibitor. VEGFR-2-IN-42 shows anti-proliferative effect against MCF7 cells with the IC₅₀ of 25 µM .

VEGFR-2-IN-42	VEGFR	Cancer
VEGFR-2-IN-42 (compound 8c) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-42 shows anti-proliferative effect against MCF7 cells with the IC₅₀ of 25 µM .

HY-149630

VEGFR2/HDAC1-IN-1	VEGFR HDAC Apoptosis	Cancer
VEGFR2/HDAC1-IN-1 (compound 13) is a potent *VEGFR-2/HDAC* dual inhibitor, with IC₅₀s of 57.83 nM and 9.82 nM, respectively. VEGFR2/HDAC1-IN-1 arrests the cell cycle at the S and G2 phases, and induces apoptosis in HeLa cells. VEGFR2/HDAC1-IN-1 exhibits anti-angiogenic effect .

HY-144796

VEGFR-2-IN-15	VEGFR Apoptosis	Cancer
VEGFR-2-IN-15 (Compound 14b) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-15 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis .

HY-131658

VEGFR-2-IN-6

VEGFR Others

VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110 .

VEGFR-2-IN-6	VEGFR	Others
VEGFR-2-IN-6 (example 64) is a *VEGFR2* inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110 .

HY-146491

VEGFR-2/BRAF-IN-1	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.049, 0.063 and 0.005 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-1 induces apoptosis and arrests the cell cycle mainly in the G1/S phase .

HY-146367

VEGFR-2-IN-19	VEGFR Apoptosis Reactive Oxygen Species	Cancer
VEGFR-2-IN-19 (Compound 15b) is a potent *VEGFR2* inhibitor. VEGFR-2-IN-19 induces cell apoptosis and increases intracellular reactive oxygen species level. VEGFR-2-IN-19 can be used as an anticancer agent .

HY-155609

VEGFR-2-IN-31	VEGFR	Cancer
VEGFR-2-IN-31 (compound 3i) is a potent *VEGFR-2* inhibitor (IC₅₀=8.93 nM), and an anti-prostate cancer agent. VEGFR-2-IN-31 arrests cell cycle at the S-phase and induces apoptosis.

HY-139822

VEGFR-2-IN-10

VEGFR Cancer

VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC₅₀ = 0.7 μM) against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.

VEGFR-2-IN-10	VEGFR	Cancer
VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC₅₀ = 0.7 μM) against VEGF-induced *VEGFR2* phosphorylation without cytotoxic effects.

HY-149024

VEGFR-2-IN-23	VEGFR Apoptosis MDM-2/p53	Cancer
VEGFR-2-IN-23 (compound 11b) is a potent and selective *VEGFR-2* inhibitor with an IC₅₀ value of 0.34 nM. VEGFR-2-IN-23 shows antitumor activity. VEGFR-2-IN-23 induces apoptosis and cell cycle arrest at G1 phase .

HY-144754

VEGFR-2-IN-13	VEGFR Apoptosis	Cancer
VEGFR-2-IN-13 (Compound 19a) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 3.4 nM. VEGFR-2-IN-13 disrupts the HepG2 cell cycle by arresting the G2/M phase and induces apoptosis .

HY-112337

VEGFR-2-IN-44	VEGFR PDGFR	Cancer
VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC₅₀ value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC₅₀ of 920 nM .

HY-163403

VEGFR-2-IN-43	VEGFR	Cardiovascular Disease Cancer
VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of *VEGFR2, with an IC₅₀* of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .

HY-157546

VEGFR-2-IN-40	VEGFR Interleukin Related Caspase	Inflammation/Immunology Cancer
VEGFR-2-IN-40 is a *VEGFR-2* inhibitor. VEGFR-2-IN-40 boosts early and late apoptosis. VEGFR-2-IN-40 decreases the levels immunomodulatory proteins TNF-α and IL-6 while showing a four-fold rise in an apoptotic marker caspase-3 .

HY-151969

VEGFR-2-IN-30	VEGFR	Cancer
VEGFR-2-IN-30 is a VEGFR-2 inhibitor (IC₅₀: 66 nM). VEGFR-2-IN-30 also inhibits PDGFR, EGFR and FGFR1 with IC₅₀s of 180, 98, 82 nM respectively. VEGFR-2-IN-30 arrests cancer cell at S-phase and induces early and late apoptosis .

HY-146230

VEGFR-2-IN-26	VEGFR	Cancer
VEGFR-2-IN-26 (compound 5h) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells .

HY-149674

VEGFR-2/c-Met-IN-1

VEGFR Cancer

VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and c-Met with IC₅₀s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity .
HY-101628

VEGFR-2-IN-9

KDR-in-4
VEGFR Cardiovascular Disease

VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC₅₀ of 7 nM.

VEGFR-2/c-Met-IN-1	VEGFR	Cancer
VEGFR-2/c-Met-IN-1 is a dual inhibitoe of *VEGFR-2 and c-Met* with *IC₅₀s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity .*

VEGFR-2-IN-9 KDR-in-4	VEGFR	Cardiovascular Disease
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC₅₀ of 7 nM.

HY-151459

VEGFR-2/DHFR-IN-2	VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal	Infection Cancer
VEGFR-2/DHFR-IN-2 (compound 5b) is an inhibitor of *VEGFR-2* and DHFR with IC₅₀s of 0.623 and 9.085 μM, respectively. VEGFR-2/DHFR-IN-2 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC₅₀ values of 3.59-8.38 μM. VEGFR-2/DHFR-IN-2 can be used for the research of cancer .

HY-151458

VEGFR-2/DHFR-IN-1	VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal	Infection Cancer
VEGFR-2/DHFR-IN-1 (compound 8b) is an inhibitor of *VEGFR-2* and DHFR with IC₅₀s of 0.384 and 7.881 μM, respectively. VEGFR-2/DHFR-IN-1 shows good antibacterial activities against Escherichia coli, Streptococcus faecalis, Salmonella enterica, MSSA and MRSA with MIC values of 16, 16, 16, 8, and 16 μg/mL, respectively. VEGFR-2/DHFR-IN-1 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC₅₀ values of 2.97-7.12 μM. VEGFR-2/DHFR-IN-1 can be used for the research of cancer .

HY-149475

VEGFR-2-IN-33	VEGFR	Cancer
VEGFR-2-IN-33 (Compound 4d) is a *VEGFR* inhibitor (IC₅₀: 61.04 nM). VEGFR-2-IN-33 inhibits HepG2 cell proliferation with an IC₅₀ of 4.31 nM. VEGFR-2-IN-33 can be used for research of hepatocellular carcinoma (HCC) .

HY-147779

VEGFR-2-IN-20

VEGFR Cancer

VEGFR-2-IN-20 (Compound 7) is a potent inhibitor of VEGFR. VEGFR-2-IN-20 has the potential for the research of cancer diseases .

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Fluorescent Dye
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively .

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Biochemical Assay Reagents
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect ^[2] .

HY-P1663

ATWLPPR Peptide 1 Publications Verification	Peptides	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

HY-P10052

CBO-P11	VEGFR	Cancer
CBO-P11 specifically binds to receptor of *VEGFR-2* and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect ^[2] .

HY-106374

Elpamotide	Peptides	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer ^[2].

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits *VEGFA/VEGFR2* expression and suppresses tumor growth in glioblastoma xenografts ^[2].

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt ^[2] .

HY-P5438

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Cat. No.	Product Name	Target	Research Area

HY-P9920

Ramucirumab 2 Publications Verification	VEGFR	Cancer
Ramucirumab is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor ^[2].

HY-P9920A

*Ramucirumab (anti-VEGFR)*	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor ^[2].

HY-P990106

Anti-Mouse VEGFR-2 Antibody (DC101)

VEGFR Cancer

Anti-Mouse VEGFR-2 Antibody (DC101) is a potent VEGFR2 inhibitor that can be used for the research of papilloma .

HY-P990147

*Anti-Mouse VEGFR-2* Antibody (DC101-CP132)**	Inhibitory Antibodies	Others
Anti-Mouse VEGFR-2 Antibody (DC101-CP132) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGFR-2.

HY-P99516

Vulinacimab HLX-06	VEGFR	Cancer
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .

HY-P99808

Pulocimab

VEGFR Cancer

Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .

HY-P99386

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer ^[2].

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human *anti-VEGFR2* monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF* signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease ^[2] .

HY-108801A

*Aflibercept (VEGF* Trap)**	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF* signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease ^[2] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0883

Gamabufotalin 4 Publications Verification Gamabufagin	Structural Classification Classification of Application Fields Animals Source classification Disease Research Fields Steroids Cancer	VEGFR
Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways.

HY-N0135

Tanshinone IIA Maximum Cited Publications 15 Publications Verification Dan Shen ketone	Quinones Structural Classification Classification of Application Fields Terpenoids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants Naphthalene Quinones Disease Research Fields Cancer	VEGFR
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-N3001

Isolinderalactone	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Lauraceae Disease Research Fields Lindera aggregata (Sims) Kosterm. Cancer	VEGFR Bcl-2 Family Survivin IAP
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of *VEGFR2* activation in endothelial cells . Isolinderalactone suppresses the expression of B-cell lymphoma 2 (Bcl-2), survi

HY-N8342

Rhamnazin	Structural Classification Combretaceae Source classification Phenols Polyphenols Plants Combretum erythrophyllum Sond.	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties ^[2].

HY-N7177

Hydroxytanshinone IIA	Quinones Classification of Application Fields Labiatae Source classification Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Cancer	Drug Metabolite VEGFR
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-12686

5Z-7-Oxozeaenol 5+ Cited Publications FR148083; L783279; LL-Z 1640-2	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Inflammation/Immunology Disease Research Fields	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-112234

L-Sepiapterin Sepiapterin	Alkaloids Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 ^S6K-dependent VEGFR-2 expression ^[2].

HY-D0803

Thymoquinone 5+ Cited Publications	Quinones Structural Classification Classification of Application Fields Nigella sativa L. Ranunculaceae Benzene Quinones Plants Inflammation/Immunology Disease Research Fields	Apoptosis VEGFR PI3K Akt
Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the *VEGFR2-PI3K-Akt* pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation ^[2] .

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[2].

HY-N2666

5α-Hydroxycostic acid	Other Terpenoids Classification of Application Fields Terpenoids Source classification Erythrina burttii Baker f. Plants Compositae Disease Research Fields Cancer	VEGFR
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and *Ang2/Tie2* pathways .

HY-N3127

Orobol	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Isoflavones	Casein Kinase PI3K VEGFR
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ) ^[2].

Species:	Human (11) Rhesus Macaque (1) Rat (2) Mouse (3) Cynomolgus (1)
Tag:	His (10) Avi (2) GST (1) Fc (7)
Source:	HEK293 (17) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P72429

	VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc) Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; NYK; CD309	Mouse	HEK293
	VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc) is 743 a.a., with molecular weight of ~138.21 kDa.

HY-P701264

	*FITC-Labeled VEGFR-2* Protein, Human (HEK293, His)** KDR; CD309; FLK1; VEGFR; VEGFR2	Human	HEK293
	VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. FITC-Labeled VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled VEGFR-2 protein, expressed by HEK293 , with His labeled tag. The total length of FITC-Labeled VEGFR-2 Protein, Human (HEK293, His) is 745 a.a., with molecular weight of 110-120 kDa.

HY-P73481

	VEGFR-2 Protein, Rat (HEK293, Fc) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309	Rat	HEK293
	VEGFR-2 Protein is a type III receptor tyrosine kinase, also known as the receptor for vascular endothelial growth factor 2. VEGFR-2 Protein mediates vascular endothelial growth factor (VEGF)-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting, and plays a key role in angiogenesis and vasculogenesis. VEGFR-2 Protein, Rat (HEK293, Fc) is the recombinant rat-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Rat (HEK293, Fc) is 760 a.a., with molecular weight of ~110 kDa.

HY-P73476

	VEGFR-2 Protein, Human (327a.a, HEK293, Fc) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (327a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Human (327a.a, HEK293, Fc) is 327 a.a., with molecular weight of ~61.5 kDa.

HY-P73477

	VEGFR-2 Protein, Human (208a.a, HEK293, Fc) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (208a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Human (208a.a, HEK293, Fc) is 208 a.a., with molecular weight of ~50.4 kDa.

HY-P73530

	VEGFR-2 Protein, Human (745a.a, HEK293, His) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (745a.a, HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGFR-2 Protein, Human (745a.a, HEK293, His) is 745 a.a., with molecular weight of ~84.6 kDa.

HY-P70552

	VEGFR-2 Protein, Human (HEK293, His) 1 Publications Verification Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR2; VEGF R2	Human	HEK293
	VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, His) is 745 a.a., with molecular weight of 84-140 kDa.

HY-P71421

	VEGFR-2 Protein, Human (HEK293, His-Avi) VEGFR2; VEGF R2; Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, His-Avi) is 745 a.a., with molecular weight of 120-150 kDa.

HY-P70635

	VEGFR-2 Protein, Human (745a.a, HEK293, Fc) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR2; VEGF R2	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (745a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Human (745a.a, HEK293, Fc) is 745 a.a., with molecular weight of 150-160 kDa.

HY-P78697

	VEGFR-2 Protein, Rhesus macaque (HEK293, His) KDR; CD309; FLK1; VEGFR; VEGFR2	Rhesus Macaque	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Rhesus macaque (HEK293, His) is 745 a.a., with molecular weight of 115-145 kDa.

HY-P74470

	VEGFR-2 Protein, Rat (HEK293, His) Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309	Rat	HEK293
	VEGFR-2 Protein is a type III receptor tyrosine kinase, also known as the receptor for vascular endothelial growth factor 2. VEGFR-2 Protein mediates vascular endothelial growth factor (VEGF)-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting, and plays a key role in angiogenesis and vasculogenesis. VEGFR-2 Protein, Rat (HEK293, His) is the recombinant rat-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Rat (HEK293, His) is 741 a.a., with molecular weight of ~115-180 kDa.

HY-P74471

	VEGFR-2 Protein, Mouse (HEK293, His) Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309	Mouse	HEK293
	VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Mouse (HEK293, His) is 762 a.a., with molecular weight of 100-110 kDa.

HY-P74473

	VEGFR-2 Protein, Cynomolgus (HEK293, His) Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309	Cynomolgus	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Cynomolgus (HEK293, His) is 745 a.a., with molecular weight of ~115-180 kDa.

HY-P74472

	VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His) Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309	Mouse	HEK293
	VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His) is 762 a.a., with molecular weight of ~84.5 kDa.

HY-P78536

	VEGFR-2 Protein, Human (HEK293, mFc) CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (HEK293, mFc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, mFc) is 745 a.a., with molecular weight of 150-200 kDa.

HY-P700850

	VEGFR-2 Protein, Human (Biotinylated, HEK293, mFc) CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, mFc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of VEGFR-2 Protein, Human (Biotinylated, HEK293, mFc) is 745 a.a., with molecular weight of 135-160 kDa.

HY-P78231

	VEGFR-2 Protein, Human (Biotinylated, HEK293, His-Avi) CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73	Human	HEK293
	VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGFR-2 Protein, Human (Biotinylated, HEK293, His-Avi) is 745 a.a., with molecular weight of 115-140 kDa.

HY-P702757

	VEGFR-2 Protein, Human (1355a.a, sf9, GST) KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); FLK1; CD309; VEGFR; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Kinase insert domain receptor; Protein-tyrosine kinase receptor Flk-1; EC 2.7.10.1; fetal liver kinase-1; soluble VEGFR2; tyrosine kinase growth factor receptor	Human	Sf9 insect cells

Cat. No.	Product Name	Chemical Structure

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

HY-15992S

BIBF 1202-13C,d3

BIBF 1202- ¹³C,d₃ is the ¹³C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-10201S2

Sorafenib-13C,d3

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Cat. No.	Product Name	Application	Reactivity

HY-P81643

VEGFR2 Antibody (YA1388) KDR; FLK1; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309	FC, ELISA	Human

HY-P81552

VEGF Receptor2 Antibody (YA1297)

FLK-1, VEGFR-2
WB Mouse


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies